Table 1 Clinicopathological variables of 176 patients with newly diagnosed AML and expression of miR-328
Clinicopathological variables | Cases (176, n/%) | miR-328 expression | P value | |
|---|---|---|---|---|
low (125) | high (51) | |||
Age (years) | ||||
≤60 | 126 (71.6) | 90 (72 %) | 36 (70.6 %) | 0.997 |
>60 | 50 (28.4) | 35 (28 %) | 15 (29.4 %) | |
Gender | ||||
Male | 86 (48.9) | 60 (48 %) | 26 (51.0 %) | 0.847 |
Female | 90 (51.1) | 65 (52 %) | 25 (49.0 %) | |
WBC (×109/L) | ||||
<10 | 73 (41.5) | 53 (42.4 %) | 30 (58.9 %) | 0.026 |
≥10 | 103 (58.5) | 82 (57.6 %) | 21 (41.1 %) | |
HGB (g/L) | ||||
<80 | 110 (62.5) | 87 (69.6 %) | 23 (45.1 %) | 0.004 |
≥80 | 66 (37.5) | 38 (30.4 %) | 28 (54.9 %) | |
PLT (×109/L) | ||||
<50 | 91 (51.7) | 72 (57.6 %) | 19 (34.2 %) | 0.022 |
≥50 | 85 (48.3) | 53 (42.4 %) | 32 (62.8 %) | |
Blast in BM | ||||
<50 % | 79 (44.9) | 45 (36 %) | 34 (66.7 %) | 0.003 |
≥50 % | 97 (55.1) | 80 (64 %) | 17 (33.3 %) | |
FAB subtype | ||||
M1 | 35 (19.9) | 25 (20 %) | 10 (19.6 %) | 0.909 |
M2 | 44 (25) | 32 (22.6 %) | 12 (23.5 %) | |
M3 | 11 (6.2) | 7 (5.6 %) | 4 (7.8 %) | |
M4 | 26 (14.8) | 20 (16 %) | 6 (11.8 %) | |
M5 | 60 (34.1) | 41 (32.8 %) | 19 (37.3 %) | |
WHO Classification | ||||
AML with t(8;21) | 19 (10.8) | 15 (12 %) | 4 (7.8 %) | 0.074 |
APL with t(15;17) | 24 (13.6) | 12 (9.6 %) | 12 (23.5 %) | |
AML without maturation | 15 (8.5) | 8 (6.4 %) | 7 (13.7 %) | |
AML with maturation | 39 (22.2) | 30 (24 %) | 9 (17.6 %) | |
Acute myelomonocytic leukemia | 26 (14.8) | 21 (16.8 %) | 5 (9.8 %) | |
Acute monoblastic and monocytic leukemia | 53 (30.1) | 39 (31.2 %) | 14 (23.6 %) | |
Karyotype classification | ||||
Favorable | 72 (40.9) | 56 (44.8 %) | 16 (31.4 %) | 0.570 |
Intermediate | 83 (47.2) | 55 (44 %) | 28 (51.9 %) | |
Unfavorable | 21 (11.9) | 14 (11.2 %) | 7 (13.7 %) | |
Complete Remission | ||||
Yes | 76 (43.2) | 55 (44 %) | 21 (41.1 %) | 0.861 |
No | 100 (56.8) | 70 (56 %) | 30 (58.9 %) | |